CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.39B, above the global median of $1.18B
- FinancialsLow earnings quality
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.12%Below 5Y avg (1.32%)
Annual Rate
CNY 0.15Paid annual
Payout Ratio
80.7%Moderate
Payback Period
97.3 yr
Last Ex-Dividend
Jul 31, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.29BCNY1.39B · vs all stocks (USD)
Trailing P/E
41.06xRevenue (TTM)
8.47BCNY1.26B · vs all stocks (USD)
Profit Margin
2.54%Beta
-0.0300xvs all stocks
52-Week Change
-17.35%vs all stocks
Market Capitalization
9.29BCNY1.39B · vs all stocks (USD)
Enterprise Value
9.01BCNY1.34B · vs all stocks (USD)
Trailing P/E
41.06xForward P/E
15.72xPrice to Sales (TTM)
1.05xPrice to Book (MRQ)
1.68xEnterprise to Revenue
1.06xEnterprise to EBITDA
10.52xGross Margin
18.20%Profit Margin
2.54%Operating Margin
2.78%Return on Assets (TTM)
1.89%Return on Equity (TTM)
4.10%Revenue (TTM)
8.47BCNY1.26B · vs all stocks (USD)
Revenue per Share (TTM)
12.23CNYUpdated Sep 18, 2026Quarterly Revenue Growth
-12.40%Gross Profit (TTM)
1.51BCNY224.68M · vs all stocks (USD)
EBITDA (TTM)
529.47MCNY78.98M · vs all stocks (USD)
Net Income (TTM)
215.26MCNY32.11M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-41.60%Operating Cash Flow (TTM)
460.21MCNY68.65M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
467.31MCNY69.70M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1500CNYUpdated Sep 18, 2026Trailing Annual Dividend Yield
1.12%vs all stocks
5-Year Average Dividend Yield
1.32%vs all stocks
Payout Ratio
80.65%Minority Interest (Equity)
246.97MCNYFY2025 · Dec 31, 2025Revenue
8.75BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
7.11BCNYFY2025 · Dec 31, 2025Gross Profit
1.64BCNYFY2025 · Dec 31, 2025Operating Income
441.55MCNY65.86M · vs all stocks (USD)
Pre-tax Income
358.92MCNYFY2025 · Dec 31, 2025Income Tax Expense
52.61MCNYFY2025 · Dec 31, 2025Net Income
306.30MCNYFY2025 · Dec 31, 2025EBIT
401.35MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.04BCNYFY2025 · Dec 31, 2025Research & Development
381.62MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
340.79MCNYFY2025 · Dec 31, 2025Other Operating Expenses
69.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.69MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
42.43MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
690.21MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
690.21MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
306.30MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-16.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-295.06MCNYFY2025 · Dec 31, 2025Free Cash Flow
-409.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.28BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
306.30MCNYFY2025 · Dec 31, 2025Other Non-cash Items
39.54MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-547.75MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-93.15MCNYFY2025 · Dec 31, 2025Capital Expenditures
-114.83MCNYFY2025 · Dec 31, 2025Sale of Investments
9.80MCNYFY2025 · Dec 31, 2025Other Investing Activity
1.53MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-103.50MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
979.80MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.11BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-209.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
59.51MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-282.15MCNYFY2025 · Dec 31, 2025Shares Outstanding
696.68MSharesUpdated Sep 18, 2026Float Shares
463.71MSharesUpdated Sep 18, 2026% Held by Insiders
49.53%vs all stocks
% Held by Institutions
0.63%vs all stocks
Total Cash (MRQ)
1.51BCNY225.38M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.17CNYUpdated Sep 18, 2026Total Debt (MRQ)
1.41BCNY210.43M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2557xCurrent Ratio (MRQ)
1.54xBook Value per Share (MRQ)
7.57CNYUpdated Sep 18, 2026Total Assets
9.19BCNY1.37B · vs all stocks (USD)
Total Current Assets
4.03BCNYFY2025 · Dec 31, 2025Total Liabilities
3.73BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.15BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
918.77MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.81BCNYFY2025 · Dec 31, 2025Cash
1.29BCNYFY2025 · Dec 31, 2025Cash Equivalents
105.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.40BCNYFY2025 · Dec 31, 2025Accounts Receivable
862.39MCNYFY2025 · Dec 31, 2025Inventory
1.32BCNYFY2025 · Dec 31, 2025Accounts Payable
1.31BCNYFY2025 · Dec 31, 2025Short-term Debt
785.80MCNYFY2025 · Dec 31, 2025Other Current Liabilities
38.59MCNYFY2025 · Dec 31, 2025Long-term Debt
696.06MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
3.56MCNYFY2025 · Dec 31, 2025Common Stock (Book)
689.78MCNYFY2025 · Dec 31, 2025Retained Earnings
2.65BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.46BCNY813.78M · vs all stocks (USD)
52-Week Low
11.71CNYUpdated Sep 18, 202652-Week High
18.70CNYUpdated Sep 18, 202652-Week Change
-17.35%vs all stocks
Beta
-0.0300xvs all stocks
50-Day MA
13.72CNYUpdated Sep 18, 2026200-Day MA
14.61CNYUpdated Sep 18, 2026Avg 10-Day Volume
6.07MSharesUpdated Sep 18, 2026Avg 30-Day Volume
11.51MSharesUpdated Sep 18, 2026Diluted EPS (TTM)
0.3100CNYUpdated Sep 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.55
Altman Z-Score 3.15: safe zoneNotable
Altman Z-Score: 3.15
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.39B, above the global median of $1.18BNotable
Market cap (USD): 1,386,256,797.402Global Median: 1,180,223,658.953
Revenue is $1.26B, above the global median of $548.88MNotable
Revenue (USD): 1,263,902,243.451Global Median: 548,883,780.48
Levered free cash flow is $69.7M, above the global median of $18.73MNotable
Levered free cash flow (USD): 69,704,315.197Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule